Page last updated: 2024-11-05

indeno(1,2,3-cd)pyrene

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

Indeno(1,2,3-cd)pyrene is a polycyclic aromatic hydrocarbon (PAH) that has been identified as a potent environmental carcinogen. It is found in coal tar, diesel exhaust, and other combustion products. Indeno(1,2,3-cd)pyrene is highly carcinogenic in laboratory animals, and has been linked to an increased risk of lung cancer in humans. Its presence in environmental samples has been associated with industrial emissions and traffic pollution. The molecule is planar and contains five fused aromatic rings, making it relatively stable and resistant to degradation. Its carcinogenic activity is believed to be related to its ability to bind to DNA and induce mutations. Indeno(1,2,3-cd)pyrene is a subject of ongoing research to better understand its biological effects and develop strategies to mitigate its environmental impact.'

indeno(1,2,3-cd)pyrene: structure in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID9131
CHEMBL ID3561582
CHEBI ID82335
MeSH IDM0123095

Synonyms (52)

Synonym
2,3-o-phenylenepyrene
ccris 345
brn 1879312
hsdb 5101
2,3-phenylenepyrene
rcra waste no. u137
einecs 205-893-2
1,10-(o-phenylene)pyrene
rcra waste number u137
indeno(1,2,3-cd)pyrene
1,10-(ortho-phenylene)pyrene
o-phenylenepyrene
indeno[1,2,3-cd]pyrene
193-39-5
inchi=1/c22h12/c1-2-7-17-16(6-1)18-11-10-14-9-8-13-4-3-5-15-12-19(17)22(18)21(14)20(13)15/h1-12
1,10-(1,2-phenylene)pyrene
indeno[1,2,3-c,d]pyrene
C19251
FT-0670326
t4swx8i0u2 ,
unii-t4swx8i0u2
AKOS015902991
indeno(1,2,3-cd)pyrene [iarc]
indeno(1,2,3-cd)pyrene [hsdb]
CHEBI:82335
cas-193-39-5
dtxsid8024153 ,
NCGC00357288-01
tox21_304020
dtxcid304153
2,3-(o-phenylene)pyrene
CHEMBL3561582
indeno[1,2,3-cd]pyrene, certified reference material, tracecert(r)
mfcd00152577
indeno(1,2,3-c,d)pyrene
indeno[1,2,3-cd]pyrene, analytical standard
indeno[1,2,3-cd]pyrene, vial of 25 mg, analytical standard
indeno[1,2,3-cd]pyrene, vial of 1 g, analytical standard
indeno[1,2,3-c,d]pyrene 100 microg/ml in acetonitrile
indeno[1,2,3-c,d]pyrene 100 microg/ml in cyclohexane
indeno[1,2,3-c,d]pyrene 10 microg/ml in acetonitrile
indeno[1,2,3-cd]pyrene; 1,10-(1,2-phenylene)pyrene; 1,10-(o-phenylene)pyrene; indeno[1,2,3-c,d]pyrene; indeno(1,2,3-c,d)pyrene
indeno[1,2,3-c,d]pyrene 10 microg/ml in cyclohexane
J-012519
Q1838431
hexacyclo[16.3.1.0^{2,7.0^{8,21.0^{11,20.0^{14,19]docosa-1(22),2,4,6,8(21),9,11(20),12,14(19),15,17-undecaene
CS-0102979
hexacyclo[16.3.1.02,7.08,21.011,20.014,19]docosa-1(22),2,4,6,8(21),9,11(20),12,14(19),15,17-undecaene
F82453
indeno[1,2,3-c,d]pyrene 1000 microg/ml in acetone
fine dust (pm10-like)-pahs
indeno(1,2,3-c,d)pyrene (d12)

Research Excerpts

Toxicity

ExcerptReferenceRelevance
" The most toxic fraction contained several known aryl hydrocarbon receptor (AhR) agonists (e."( Effect-directed analysis of Elizabeth River porewater: developmental toxicity in zebrafish (Danio rerio).
Clark, BW; Cooper, EM; Di Giulio, RT; Fang, M; Ferguson, PL; Garner, LV; Getzinger, GJ; Stapleton, HM, 2014
)
0.4
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Drug Classes (1)

ClassDescription
pyrenes
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Protein Targets (16)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
LuciferasePhotinus pyralis (common eastern firefly)Potency10.96400.007215.758889.3584AID1224835
hypoxia-inducible factor 1 alpha subunitHomo sapiens (human)Potency23.91453.189029.884159.4836AID1224846
SMAD family member 2Homo sapiens (human)Potency18.19090.173734.304761.8120AID1346859; AID1346924; AID1347035
SMAD family member 3Homo sapiens (human)Potency18.19090.173734.304761.8120AID1346859; AID1346924; AID1347035
GLI family zinc finger 3Homo sapiens (human)Potency0.00940.000714.592883.7951AID1259369; AID1259392
AR proteinHomo sapiens (human)Potency4.85680.000221.22318,912.5098AID1259243; AID1259247
estrogen receptor 2 (ER beta)Homo sapiens (human)Potency10.59090.000657.913322,387.1992AID1259377; AID1259378
nuclear receptor subfamily 1, group I, member 3Homo sapiens (human)Potency5.93080.001022.650876.6163AID1224838; AID1224839; AID1224893
progesterone receptorHomo sapiens (human)Potency8.46850.000417.946075.1148AID1346784; AID1346795
retinoid X nuclear receptor alphaHomo sapiens (human)Potency7.76380.000817.505159.3239AID1159527; AID1159531
estrogen-related nuclear receptor alphaHomo sapiens (human)Potency16.78990.001530.607315,848.9004AID1224841; AID1224848; AID1224849
estrogen nuclear receptor alphaHomo sapiens (human)Potency0.21130.000229.305416,493.5996AID1259244; AID1259248
thyroid stimulating hormone receptorHomo sapiens (human)Potency29.84930.001628.015177.1139AID1259385
v-jun sarcoma virus 17 oncogene homolog (avian)Homo sapiens (human)Potency8.48520.057821.109761.2679AID1159526
Voltage-dependent calcium channel gamma-2 subunitMus musculus (house mouse)Potency0.21130.001557.789015,848.9004AID1259244
Glutamate receptor 2Rattus norvegicus (Norway rat)Potency0.21130.001551.739315,848.9004AID1259244
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Ceullar Components (1)

Processvia Protein(s)Taxonomy
plasma membraneGlutamate receptor 2Rattus norvegicus (Norway rat)
[Information is prepared from geneontology information from the June-17-2024 release]

Research

Studies (24)

TimeframeStudies, This Drug (%)All Drugs %
pre-19906 (25.00)18.7374
1990's1 (4.17)18.2507
2000's1 (4.17)29.6817
2010's15 (62.50)24.3611
2020's1 (4.17)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 42.16

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be strong demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index42.16 (24.57)
Research Supply Index3.26 (2.92)
Research Growth Index5.49 (4.65)
Search Engine Demand Index56.80 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (42.16)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other25 (100.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]